Publicacións (31) Publicacións de Jesús García. Gómez

2024

  1. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study

    eClinicalMedicine, Vol. 73

2023

  1. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative

    Supportive Care in Cancer, Vol. 31, Núm. 12

  2. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2634-2646

  3. The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer

    Oncologist, Vol. 28, Núm. 10, pp. E902-E909

2022

  1. Emesis y quimioterapia. Más allá de los setrones y los antagonistas del receptor NK1

    Revisiones en Cancer, Vol. 36, Núm. 2, pp. 104-112

  2. Establishing an Expert Consensus on Key Indicators of the Quality of Life among Breast Cancer Survivors: A Modified Delphi Study

    Journal of Clinical Medicine, Vol. 11, Núm. 7

2021

  1. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1272-1280

  2. PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study

    Oncology Letters, Vol. 22, Núm. 1

  3. Patients-centered SurvivorShIp care plan after Cancer treatments based on Big Data and Artificial Intelligence technologies (PERSIST): a multicenter study protocol to evaluate efficacy of digital tools supporting cancer survivors

    BMC Medical Informatics and Decision Making, Vol. 21, Núm. 1

  4. SEOM clinical guideline for management of adult medulloblastoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947

2020

  1. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359

2019

  1. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

    Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889

  2. Proyecto ADAPTA: Adecuación del tratamiento en dolor irruptivo oncológico

    Revista de la Sociedad Espanola del Dolor, Vol. 26, Núm. 1, pp. 31-43

  3. Tratamiento perioperatorio en cáncer de vejiga: Revisión de la literatura

    Revisiones en Cancer, Vol. 33, Núm. 5, pp. 210-215

2018

  1. Epidemiología y factores pronósticos de los tumores neuroendocrinos

    Revisiones en Cancer, Vol. 32, Núm. 5, pp. 287-293

2016

  1. Ki-67 is a prognostic marker for hormone receptor positive tumors

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 996-1002

2014

  1. Emesis y quimioterapia. Más allá de los setrones y los antagonistas del receptor NK1

    Revisiones en Cancer, Vol. 28, Núm. 4, pp. 175-183

  2. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

    Cancer, Vol. 120, Núm. 10, pp. 1453-1461

2013

  1. SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013

    Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1030-1036

  2. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

    Supportive Care in Cancer, Vol. 21, Núm. 1, pp. 343-355